Platinum versus non-platinum chemotherapy regimens for small cell lung cancer

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 8, 2015, Pages

  Amarasena, Isuru U ^a   Chatterjee, Saion ^b   Walters, Julia A E ^a   Wood Baker, Richard ^a   Fong, Kwun M ^c  

^a UNIVERSITY OF TASMANIA   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; AMRUBICIN; CARBOPLATIN; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; LOMUSTINE; MAYTANSINE; METHOTREXATE; METOCLOPRAMIDE; MITOMYCIN; PACLITAXEL; PLATINUM COMPLEX; TOPOTECAN; VINBLASTINE; VINCRISTINE; VINDESINE; WARFARIN; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ALOPECIA; ANEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SMALL CELL LUNG CANCER; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; LUNG NEOPLASMS; META ANALYSIS; MORTALITY; SMALL CELL LUNG CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LUNG NEOPLASMS; PLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84991241025     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006849.pub3     Document Type: Review

References (72)

1. Baka S, Califano R, Ferraldeschi R, Ashcroft L, Thatcher N, Taylor P, et al. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. British Journal of Cancer 2008;99(3):442-7.
2. Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. Journal of Clinical Oncology 1989 Aug;7(8):993-1002.
3. Creech RH, Stanley K, Vogl SE, Ettinger DS, Bonomi PD, Salazar O. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). Cancer Treatment Reports 1982 Jun;66(6):1417-9.
4. De Jong WK, Groen HJ, Koolen MG, Biesma B, Willems LN, Kwa HB, et al. Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. European Journal of Cancer 2007;43:2345-2350.
5. Eagan RT, Lee RE, Frytak S, Fleming TR, Ingle JN, Creagan ET, et al. An evaluation of low-dose cisplatin as part of combined modality therapy of limited small cell lung cancer. Cancer Clinical Trials 1981;4(3):267-71.
6. Evans WK, Feld R, Murray N, Willan A, Coy P, Osoba D, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Annals of Internal Medicine 1987 Oct;107(4):451-8.
7. Farris A, Bisail M, Sarobba MG, Sanna G, Scotto T, Valzelli S, et al. Cisplatin-VP16 alternating with cyclophosphamide-epirubicin versus cyclophosphamide-epirubicin-vincristine in small cell lung cancer. Journal of Chemotherapy 1993 Oct;5(5):344-7.
8. Fukuoka M, Takada M, Negoro S, Kusunoki Y, Matsui K, Ryu S, et al. Alternating non-cross resistant chemotherapy for small cell lung cancer. Japanese Journal of Clinical Oncology 1986 Sep;16(3):261-70.
9. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. Journal of the National Cancer Institute 1991 Jun 19;83(12):855-61.
10. Gatzemeier U, Pawel JV, Laumen R, Hossfeld DK, Neuhauss R. Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial. Seminars in Oncology 1994 Jun;21(3 Suppl 6):31-5.
11. Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, et al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. Journal of Clinical Oncology 1990 Jan;8(1):39-47.
12. Greco FA, Thompson DS, Morrissey LH, Erland JB, Burris HA, Spigel DR, et al. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial. Oncologist 2005 Oct;10(9):728-33.
13. Havemann K, Wolf M, Holle R, Gropp C, Drings P, Manke HG, et al. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial. Cancer 1987 Mar 15;59(6):1072-82.
14. Jones AL, Holborn J, Ashley S, Smith IE. CVM versus ACE in the treatment of small cell lung cancer. Oncology 1993 Nov;50 Suppl 2:10-5.
15. Kanitz E, Kolaric K, Jassem J, Mechl Z, Pawlicki M, Ringwald G, et al. Randomized phase II trial of high-dose 4'-epi-doxorubicin + cyclophosphamide versus high-dose 4'-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer. Oncology 1992;49(5):327-32.
16. Lyss AP, Herndon JE, Lynch TJ, Turrisi AT, Watson DM, Grethlein SJ, et al. Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clinical Lung Cancer 2002 Feb;3(3):205-10; discussion 11-2.
17. Postmus PE, Splinter TA, Palmen FM, Carney DN, Festen J, Burghouts JT, et al. Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group. European Journal of Cancer 1992;28(1):96-100.
18. Postmus PE, Scagliotti G, Groen HJ, Gozzelino F, Burghouts JT, Curran D, et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. European Journal Cancer 1996 Aug;32A(9):1498-503.
19. Quoix E, Breton JL, Gervais R, Wilson J, Schramel F, Cardenal F, et al. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Lung Cancer 2005 Aug;49(2):253-61.
20. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. Journal of Clinical Oncology 1992 Feb;10(2):282-91.
21. Sculier JP, Klastersky J, Libert P, Ravez P, Thiriaux J, Lecomte J, et al. A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party. Annals of Oncology 1990;1(2):128-33.
22. Sculier JP, Paesmans M, Bureau G, Dabouis G, Libert P, Vandermoten G, et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. Journal of Clinical Oncology 1993 Oct;11(10):1858-65.
23. Sekine I, Okamoto H, Horai T, Nakagawa K, Ohmatsu H, Yokoyama A, et al. A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer. Clinical Lung Cancer 2014;15(2):96-102.
24. Smith AP, Anderson G, Chappell G, Bowen DR. Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens. Thorax 1991 Mar;46(3):172-4.
25. Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. Journal of the National Cancer Institute 1997 Apr 16;89(8):577-80.
26. Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. Journal of Clinical Oncology 2002 Dec 15;20(24):4665-72.
27. Urban T, Baleyte T, Chastang CL, Jeannin L, Delaval P, Zaegel M, et al. Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group. Lung Cancer 1999 Aug;25(2):105-13.
28. Urban T, Chastang C, Lebas FX, Duhamel JP, Adam G, Darse J, et al. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. 'Petites Cellules' Group. Cancer 1999 Dec 1;86(11):2238-45.
29. Veronesi A, Cartei G, Crivellari D, Magri MD, Della Valentina M, Foladore S, et al. Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study. European Journal of Cancer 1994;30A(10):1474-8.
30. Wampler GL, Heim WJ, Ellison NM, Ahlgren JD, Fryer JG. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study. Journal of Clinical Oncology 1991 Aug;9(8):1438-45.
31. White SC, Lorigan P, Middleton MR, Anderson H, Valle J, Summers Y, et al. Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. Cancer 2001 Aug 1;92(3):601-8.
32. Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, et al. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. Journal of Clinical Oncology 1987 Dec;5(12):1880-9.
33. Artel-Cortes A, Gomez-Codina J, Gonzalez-Larriba JL, Barneto I, Carrato A, Isla D, et al. Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. Clinical Lung Cancer 2004 Nov;6(3):175-83.
34. Blackstock AW, Bogart JA, Matthews C, Lovato JF, McCoy T, Livengood K, et al. Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial. Clinical Lung Cancer 2005 Mar;6(5):287-92.
35. De Marinis F, Nelli F, Lombardo M, Ferrau F, Barbera S, Bertetto O, et al. A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma. Cancer 2005 Feb 15;103(4):772-9.
36. Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. Journal of Clinical Oncology 2006 May 1;24(13):2044-51.
37. Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. Journal of Clinical Oncology 2006 May 1;24(13):2038-43.
38. Lara PN Jr, Gandara DR, Natale RB. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clinical Lung Cancer 2006 Mar;7(5):353-6.
39. McClay EF, Bogart J, Herndon JE, Watson D, Evans L, Seagren SL, et al. A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). American Journal of Clinical Oncology 2005 Feb;28(1):81-90.
40. Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology 2005 Jun 1;23(16):3752-9.
41. Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 2004 Jan;43(1):83-91.
42. Pathak AK, Bhutani M, Guleria R, Bal S, Mohan A, Mohanti BK, et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. Journal of the American College of Nutrition 2005 Feb;24(1):16-21.
43. Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. International Journal of Radiation, Oncology, Biology, Physics 2004 Jul 15;59(4):943-51.
44. Seifart U, Jensen K, Ukena J, Mueller C, Schroder M, Fuhr HG, et al. Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). Lung Cancer 2005 Jun;48(3):415-22.
45. Abeloff MD. Clinical oncology. 3rd Edition. Philadelphia, Pa: Elsevier Churchill Livingstone, 2004.
46. ACN . Clinical practice guidelines for the prevention, diagnosis and management of lung cancer. Clinical practice guidelines for the prevention, diagnosis and management of lung cancer. Sidney: Cancer Council Australia, 2004.
47. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest Jan 2003;123(1 Suppl):21S-49S.
48. Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, et al. What is a clinically meaningful change on the FACT-L Questionnaire? Results of ECOG study 5592. J Clin Epidemiology 2002;55(3):285-95.
49. Chabner BA, Longo DL. Cancer Chemotherapy and Biotherapy: Principles and Practice (Chabner, Cancer Chemotherapy and Biotherapy). 5. LWW, December 2010.
50. Chan BA, Coward JI. Chemotherapy advances in small-cell lung cancer. Journal of Thoracic Disease October 2013;5(Supplement 5):S565-S578.
51. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clinics in Chest Medicine December 2011;32(4):605-644.
52. Evans WK, Feld R, Murray N, Pater J, Shelley W, Willan A, et al. The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer. Seminars in Oncology 1986;13(3 (Suppl 3)):10-6.
53. Glisson BS, Byers LA. Pathobiology and staging of small cell carcinoma of the lung. UpToDate. Waltham, MA: UpToDate, Nov 2014.
54. Gralla RJ. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. Oncologist 2004;9 Suppl 6:14-24.
55. Gusi N, Olivares PR, Rajendram R. The EQ-5D Health-Related Quality of Life Questionnaire. Handbook of Disease Burdens and Quality of Life Measures. Springer New York, 2010:87-99.
56. Heintz NH, Janssen-Heininger YM, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. American Journal of Respiratory Cell and Molecular Biology Feb 2010;42(2):133-139.
57. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
58. Higgins JPT, Deeks JJ (editors). Chapter 7. Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Chichester, UK: John Wiley & Sons for The Cochrane Collaboration.
59. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
60. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
61. Le Pechoux C, Dhermain F, Bretel JJ, Laplanche A, Dunant A, Tarayre M, et al. Modalities of radiotherapy in small cell lung cancer: thoracic radiotherapy and prophylactic cerebral irradiation. Revue de Pneumologie Clinique 2004;3S:91-103.
62. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
63. Micke P, Faldum A, Metz T, Beeh K-M, Bittinger F, Hengstler J-G, Buhl R. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - what limits limited disease?. Lung Cancer September 2002;37(3):271-276.
64. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Japanese Journal of Clinical Oncology September 2003;33(10):533-537.
65. Peckham MJ, Pinedo HM, Veronesi U. Oxford Textbook of Oncology. Oxford University Press, 1995.
66. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. British Journal of Cancer 2000;83(1):8-15.
67. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
68. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
69. Stinchcombe TE, Gore EM. Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms. The Oncologist Feb 2010;15(2):187-195.
70. Stubblefield M, O'Dell M. Cancer Rehabilitation: Principles and Practice. New York City: Demos Medical Publishing, Apr 22, 2009.
71. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO offset publication no 48. Geneva, Switzerland: World Health Organization, 1979.
72. Amarasena IU, Walters JA, Wood-Baker R, Fong K. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database of Systematic Reviews 2008, Issue Oct 8;(4):CD006849. [DOI: 10.1002/14651858.CD006849.pub2]